MiniMed Flex (formerly NMX8-AID)
MiniMed
MiniMed's FDA-cleared, screenless, smartphone-controlled successor to the 780G pump line. Flex uses SmartGuard advanced hybrid closed-loop automation, Simplera Sync CGM, a 300-unit reservoir, 7-day rechargeable battery and app bolusing. GATEWAY — an interventional safety study, not a passive registry — still tests it under the NMX8-AID name and includes flexible/no-meal-bolus arms, but public Flex performance data are not yet as mature as 780G real-world data.
The scorecard
Uses MiniMed SmartGuard automation, whose predecessor 780G has strong real-world evidence, but Flex-specific GATEWAY outcomes are not posted yet; scored below mature 780G until direct data report.[1]
SmartGuard includes predictive low suspend and automated basal/correction behavior, and the GATEWAY safety study directly measures time below 70 mg/dL (3.9 mmol/L), but Flex-specific safety outcomes are still pending — primary completion is not due until January 2027.[3]
Product release is an advanced hybrid loop with app bolusing; GATEWAY randomises participants to bolus, not bolus, or bolus at will for meals, making this a real step toward lower-burden meal automation. Scored on the shipped hybrid loop, not on the unproven no-bolus arm.[3]
Smaller, screenless, smartphone-controlled pump with app meal/correction boluses and a 7-day battery is freer than a classic pump body, but it remains tubed.[1]
Expected to inherit SmartGuard glucose performance, but no Flex-specific mean glucose, GMI, or HbA1c results have been posted.[1]
SmartGuard should reduce excursions through automated correction and basal changes, but GATEWAY variability results are still unavailable.[3]
The safety study collects exercise logs and SmartGuard includes low protection, but no Flex-specific exercise-mode results are public.[3]
The system supports app control, SmartGuard settings, and the meal modes under study, but it remains a closed MiniMed ecosystem rather than a deeply tunable algorithm.[1]
FDA-cleared in the US for T1D ages 7+ and insulin-requiring T2D adults, with a select-customer spring 2026 launch and US commercial rollout under way through summer 2026; pricing and ex-US rollout are still unclear.[2]
Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.
The full picture
MiniMed Flex is the public product name for the next-generation system that the GATEWAY study still calls NMX8-AID. It is now FDA-cleared in the United States: a small screenless pump controlled through the MiniMed app, paired with SmartGuard automation, Simplera Sync CGM, standard MiniMed infusion sets, a 300-unit reservoir and a rechargeable battery lasting at least seven days. The US commercial rollout, with Simplera Sync as the paired sensor, has been running through the summer of 2026.
The reason it stays in the "frontier" set is the GATEWAY protocol. GATEWAY is an interventional safety study — not a passive registry — enrolling 400 people and randomising them to bolus, not bolus, or bolus at will for meals. A licensed system with a formally studied no-meal-bolus arm is a direct move toward lower-burden meal automation.
The caveat is evidence maturity, and it has not changed. The pump is cleared, but public Flex-specific time-in-range, hypoglycemia and no-meal-bolus outcomes are not posted yet; GATEWAY's primary completion is not due until January 2027. Everything we currently score is inherited from SmartGuard's track record on the 780G, not measured on Flex. Until direct results arrive, Flex should be treated as an approved hardware and control upgrade with a promising automation direction, not as proven fully closed loop.
What is reported next — and how firmly
Flex is also the platform MiniMed has said will carry Vivera, a next generation algorithm whose headline promise is making the meal bolus optional rather than required. A conference recap from ADA 2026 reports a Vivera software update in 2027, integration with the Abbott-built Instinct sensor in Q3 2026, and a European launch in early 2027.1 Treat those three timings as reported, not confirmed: they come from a community conference write-up, and MiniMed's own newsroom has announced the European Instinct launch for the 780G and MiniMed Go rather than for Flex. Dates on this record will firm up only when MiniMed states them directly.
References
-
Closed-loop updates from ADA 2026 — community conference recap, June 2026. ↩
What's next for this
- →Abbott-built Instinct sensor integration (reported at ADA 2026, unconfirmed by MiniMed) · reported for Q3 2026
- →European launch (reported at ADA 2026, unconfirmed by MiniMed) · reported for early 2027
- →Vivera algorithm software update (optional meal bolusing), reported at ADA 2026 · reported for 2027
- →GATEWAY safety study completion and meal-mode data · primary completion estimated January 2027
Sources
- [1]MiniMed Flex system product FAQ · manufacturer
- [2]MiniMed announces FDA clearance of MiniMed Flex, its smallest insulin pump and first smartphone-controlled design · manufacturer · 2026-03-18
- [3]GATEWAY Safety Evaluation of the MiniMed NMX8-AID System in Children and Adults Living With Diabetes · registry · 2026-06-08 — NCT07228117. Interventional safety study (not a passive registry), n=400, recruiting, started 2 Feb 2026, primary completion January 2027. Randomises participants to bolus, not bolus, or bolus at will for meals.
- [4]Closed-loop updates from ADA 2026: MiniMed Flex, Instinct and Vivera · community · 2026-06-25 — Community conference recap, not a company announcement. Sole source for the reported Instinct-integration and European-launch timings, so those are attributed rather than stated as fact.